

25 February 2025

**Aptamer Group plc**

("Aptamer", the "Company" or the "Group")

**Notice of Results and Investor Presentation**

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2024 on Tuesday, 11 March 2025.

The Company is pleased to announce that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer, will provide a live presentation relating to the interim results via Investor Meet Company on Tuesday, 11 March 2025, at 14:00 GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until Monday, 10 March 2025, 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via:  
<https://www.investormeetcompany.com/aptamer-group-plc/register-investor>

Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited.

- Ends -

**For further information, please contact:**

<b>Aptamer Group plc</b>	+44 (0) 1904 217 404
Arron Tolley, Chief Executive Officer	
<b>SPARK Advisory Partners Limited - Nominated Adviser</b>	+44 (0) 20 3368 3550
Andrew Emmott / Jade Bayat	
<b>Turner Pope Investments (TPI) Limited - Broker</b>	+44 (0) 20 3657 0050
James Pope / Andrew Thacker	
<b>Northstar Communications Limited - Investor Relations</b>	+44 (0) 113 730 3896
Sarah Hollins	

**About Aptamer Group plc**

Aptamer Group is a leading global developer of aptamer-based ligands that help scientists remove the limits to discovery and innovation. Leveraging several proprietary discovery and development platform, Aptamer delivers custom affinity ligands, supported with a complete suite of characterisation and validity assays that enhance the translation of its binders and optimise scientific outcomes for customers.

Aptamer's cutting-edge technology spans healthcare, research, personal care, and industrial processes, delivering new affinity solutions for novel targets, advanced diagnostics, and precision therapies. By working with industry leaders in pharmaceutical, biotechnology, personal health, academic, and clinical research sectors, Aptamer is accelerating science through the custom development of tools and therapies.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORTIMRTMTTBA